<DOC>
	<DOCNO>NCT01024413</DOCNO>
	<brief_summary>This randomize controlled trial compare efficacy safety erlotinib gefitinib advance NSCLC harbor EGFR exon 19 21 mutations.Eligible patient randomize receive erlotinib gefitinib line settings.The primary endpoint progression-free survival ( PFS ) .</brief_summary>
	<brief_title>Phase III Trial Evaluate Elortinib v Gefitinib Advanced NSCLC With EGFR Exon 19 21 Mutations</brief_title>
	<detailed_description>Patients stage IV NSCLC EGFR exon 19 21 mutation randomize received oral erlotinib 150mg gefitinib 250mg daily disease progression unacceptable toxicity . Method direct DNA sequence tumor tissue use analysis EGFR mutation status exon 18-21 . The response evaluate RECIST criterion first month , second month repeat every 3 month begin treatment week .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB ( wet ) IV NSCLC . Patients positive EGFR exon19 exon21 mutation confirm direct sequencing histologically . Signing informed consent form . The vital organ function tolerant therapy . Have recover CTCAE2 grade toxicity previous chemotherapy radiotherapy PS 02 score . Functional reserve bone marrow adequate , e.g . white blood cell count ≥3.0×109/L , planet count ≥90×109/L , HB≥80×109/L . Serum bilirubin 2 time less upper limit normal ( ULN ) , ALT AST 3 time less ULN ; liver metastasis , ALT AST need 5 time less ULN ; creatinine 2 time less ULN . Informed consent provide . Women pregnancy breastfeed . Have difficulty swallowing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Epidermal growth factor receptor gene</keyword>
</DOC>